Help Patients Get to Goal With Heart Failure Meds
January 2023
Questions will come up about the best way to titrate meds for heart failure with reduced ejection fraction (HFrEF).
Less than 1% of patients are on target-dose “triple therapy” with an ACEI, ARB, or Entresto (sacubitril/valsartan)...an evidence-based beta-blocker (carvedilol, etc)...and an aldosterone antagonist.
Even fewer get the latest guideline-recommended “quad therapy” for HFrEF...by adding an SGLT2 inhibitor (Forxiga, etc).
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive